Benefits
Cholesterol: the largest trial found LDL went UP
The strongest trial found the opposite of a benefit. In the 2003 JAMA study of 103 U.S. adults with high cholesterol taking guggulipid for 8 weeks, LDL fell 5 percent on placebo but rose 4 percent on the standard dose and 5 percent on the high dose, a net increase of about 9 percent (P=0.01) and 10 percent (P=0.006) versus placebo. Total cholesterol, HDL, triglycerides and VLDL did not change significantly. A 2009 Norwegian trial (43 enrolled, 34 completed, 2,160 mg a day for 12 weeks) lowered total cholesterol but also lowered HDL, which is not a benefit, and left LDL, triglycerides and the total/HDL ratio unchanged. Only one older and smaller trial, 61 patients in India taking 50 mg guggulipid twice daily for 24 weeks alongside a diet program, reported drops of 11.7 percent in total cholesterol, 12.5 percent in LDL and 12.0 percent in triglycerides. Taken together the human evidence does not support guggul for cholesterol.
Possible Anti-Inflammatory Activity
This is laboratory work, not evidence in people. Guggulsterones reduce NF-kB signaling and inflammatory cytokines in cell studies, and guggul has a long traditional use for arthritis in Ayurveda. None of the human trials cited on this page measured joint pain or inflammation, so there is no clinical evidence here that guggul does anything for either.
Traditional Ayurvedic Indications
Guggul has been used in Ayurveda for centuries for obesity, high blood fats, arthritis and inflammatory complaints. Reviews of the plant describe more than 300 compounds and many effects seen in cells and animals. Traditional use and laboratory activity are not evidence that guggul works for any of these in people, and no human trial of guggul for weight or arthritis is cited on this page.
Thyroid: an animal idea, but a human harm signal
Animal studies suggest guggul may stimulate thyroid function, possibly by increasing an enzyme that converts T4 into active T3. No human trial supports a thyroid benefit. In the human evidence, thyroid effects show up on the harm side rather than the benefit side: two participants taking guggul in the 2009 Norwegian trial had possible thyroid problems. Anyone with a thyroid condition or taking thyroid medication should avoid guggul unless a clinician says otherwise.
Antioxidant Effects
One trial, the 1994 study of 61 patients with high cholesterol in India, reported a 33.3 percent drop in lipid peroxides, a laboratory marker of oxidative stress, with no change on placebo. That is a single small study that has not been repeated, and a change in a lab marker is not the same as a health benefit. The two later trials found no cardiovascular benefit, and the JAMA trial found LDL went up.
Mechanism of action
FXR (Farnesoid X Receptor) Antagonism
Guggulsterones are antagonist ligands at FXR — a nuclear receptor regulating bile acid synthesis and cholesterol metabolism. The idea is that blocking FXR frees the liver to turn more cholesterol into bile acids, which could lower blood cholesterol. This is the main proposed mechanism, but it did not hold up in people: the JAMA trial that tested it found LDL rose rather than fell.
Pregnane X Receptor (PXR) Modulation
Guggulsterones also modulate PXR, another nuclear receptor involved in xenobiotic metabolism and lipid homeostasis. The dual FXR/PXR activity may explain both lipid-modulating effects and the documented potential for drug interactions.
NF-κB Signaling Inhibition
Z-guggulsterone blocks NF-kB activation in cell studies, which lowers production of inflammatory signals such as TNF-alpha, IL-1beta and IL-6. This is the proposed explanation for anti-inflammatory effects seen in animal models of arthritis and bowel inflammation. It has not been tested in people.
Antioxidant Activity
Guggul contains resin and polyphenol compounds that mop up free radicals in the test tube and may switch on the body's own antioxidant enzymes. The 33 percent drop in lipid peroxides comes from one small 1994 trial and has not been repeated, so what it means for health is unknown.
Bile Acid Metabolism Effects
Through FXR antagonism, guggul increases hepatic cholesterol conversion to bile acids, which are then excreted in feces. This is loosely similar to how prescription bile acid binders work, but it stays a theory: in the human trials guggul did not lower LDL, and in the JAMA trial LDL went up.
Clinical trials
Double-blind, randomized, placebo-controlled trial in 103 U.S. adults with high cholesterol eating a typical Western diet. Guggulipid standardized to 2.5 percent guggulsterones, 1,000 mg or 2,000 mg three times daily for 8 weeks. (Szapary and colleagues, JAMA 2003; PMID 12915429)
103 adults with diagnosed high cholesterol, eating a typical Western diet, treated for 8 weeks.
The trial missed its main goal and the result went the wrong way. LDL fell 5 percent on placebo but rose 4 percent on the standard dose and 5 percent on the high dose, a net increase of about 9 percent (P=0.01) and 10 percent (P=0.006) versus placebo. Total cholesterol, HDL, triglycerides and VLDL did not change significantly. Six people taking guggulipid developed a hypersensitivity rash and nobody on placebo did. The authors wrote that guggulipid did not appear to improve serum cholesterol over the short term and might in fact raise LDL.
Randomized, double-blind trial of 50 mg guggulipid or placebo capsules twice daily for 24 weeks as adjunct to a fruit and vegetable-enriched prudent diet in patients with hypercholesterolemia. (Singh, Niaz and Ghosh, Cardiovasc Drugs Ther 1994; PMID 7848901)
61 patients (31 guggulipid, 30 placebo). Compliance >96%.
Guggulipid + diet reduced total cholesterol -11.7%, LDL -12.5%, triglycerides -12.0%, total/HDL ratio -11.1% from postdiet levels. HDL was unchanged. Lipid peroxides declined 33.3% in guggulipid group vs no change in placebo. The authors compared the combined diet plus guggulipid effect favorably with lipid-lowering drugs, but this was one small trial in patients being treated for high cholesterol, the guggul effect cannot be separated cleanly from the diet program, and the result was not reproduced in the two later Western trials. A few patients had headache, mild nausea, belching or hiccups.
Double-blind, randomized, placebo-controlled trial in Norwegian general practice. 2,160 mg/day guggul (4 capsules) or placebo for 12 weeks in healthy adults with moderately increased cholesterol. (Nohr, Rasmussen and Straand, Complement Ther Med 2009; PMID 19114224)
43 women and men aged 27 to 70 with moderately raised cholesterol were enrolled; 34 completed the study.
After 12 weeks total cholesterol fell, but so did HDL, the cholesterol you do not want to lower, so this is not a clear benefit. LDL, triglycerides and the total/HDL ratio did not differ from placebo. Adverse events were more common on guggul: 10 users versus 4 on placebo, including stomach upset in 7, possible thyroid problems in 2, and one generalized skin rash in a person who withdrew. The authors wrote that the clinical magnitude of this remains obscure and that more and larger studies are needed to establish effects and safety.
Comprehensive evidence review of guggul for hyperlipidemia by the Natural Standard Research Collaboration. Reviews efficacy in humans, dosing, precautions, adverse effects, pregnancy/lactation use, interactions, and mechanism of action. (Ulbricht and colleagues, Complement Ther Med). This is a narrative evidence review, not a clinical trial, and it is not among the three PubMed references cited on this page.
Comprehensive literature review of human trials.
Before 2003, mostly small Indian trials reported that guggulipid lowered total cholesterol, LDL and triglycerides and raised HDL. The 2003 JAMA trial, the largest and best controlled test, found no benefit and an increase in LDL, which overturns that earlier picture rather than merely complicating it. Authors concluded evidence is mixed; recommendations for use should be tempered by population-specific concerns and quality standardization issues.
Comprehensive review of Commiphora genus ethnopharmacology, phytochemistry, pharmacology, artificial cultivation, and quality control. (Garang and colleagues, J Ethnopharmacol). This is a literature review of mostly laboratory and animal work, not a clinical trial, and it is not among the references cited on this page.
Literature review across multiple databases.
Identifies more than 300 compounds in Commiphora species. E- and Z-guggulsterone show a range of activities in cells and in animals, including anti-proliferative, antioxidant, anti-inflammatory and antibacterial effects. None of this is evidence of a benefit in people. Authors emphasize ongoing concerns about C. mukul as endangered species (IUCN Red List) and quality standardization challenges across commercial products.